Market closed

AC Immune/$ACIU

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About AC Immune

AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.

Ticker

$ACIU
Sector
Health Care
Trading on
NASDAQ

Industry

Biotechnology

Headquarters

Lausanne, Switzerland

Employees

147
Website
www.acimmune.com

AC Immune Metrics

BasicAdvanced
$291M
-
-$0.76
1.27
-

$291M

1.27

$5.14

$2.25

80K

1.796

1.757

2.06

2.616

-492.10%

-19.06%

-46.06%

15.194

2.37

4.01

5.373

293.60%

-17.96%

95.71%

-14.12%

What the Analysts think about AC Immune

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for AC Immune stock.

AC Immune Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

AC Immune Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $ACIU

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for AC Immune stock?

AC Immune (ACIU) has a market cap of $291M as of January 15, 2025.

What is the P/E ratio for AC Immune stock?

The price to earnings (P/E) ratio for AC Immune (ACIU) stock is 0 as of January 15, 2025.

Does AC Immune stock pay dividends?

No, AC Immune (ACIU) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next AC Immune dividend payment date?

AC Immune (ACIU) stock does not pay dividends to its shareholders.

What is the beta indicator for AC Immune?

AC Immune (ACIU) has a beta rating of 1.27. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.